Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tohoru Nakamichi"'
Autor:
Aki Kobayashi, Takashi Yokoi, Takaji Matsutani, Ayumi Kuroda, Kazutaka Kitaura, Akifumi Nakamura, Ryuji Suzuki, Tohoru Nakamichi, Nobuyuki Kondo, Koichiro Yamakado, Hiroshi Kodama, Seiji Matsumoto, Masaki Hashimoto, Ryo Takahashi, Yoshiko Fujita, Yoshie Inao, Seiki Hasegawa, Takashi Kijima
Publikováno v:
Cancer Research. 80:4478-4478
Background: Programmed death 1 (PD-1) blockade with Nivolumab are effective in patients with malignant pleural mesothelioma (MPM), however; successful predictive biomarker has not been available. Unlike invasive test with tumor biopsy, peripheral blo
Autor:
Takaji Matsutani, Seiji Matsumoto, Ryuji Suzuki, Masaki Hashimoto, Akifumi Nakamura, Yoshiko Fujita, Ayumi Kuroda, Tohoru Nakamichi, Kazutaka Kitaura, Seiki Hasegawa, Nobuyuki Kondo
Publikováno v:
Cancer Research. 79:2230-2230
Background: Anti-PD-1 antibodies (nivolumab) are effective in the treatment of many cancers, including malignant melanoma, non-small cell lung cancer (NSCLC), renal cell cancer, and head and neck squamous cell carcinoma. Immune checkpoint inhibitors
Autor:
Masaki Hashimoto, Tohoru Nakamichi, Ayumi Kuroda, Nobuyuki Kondo, Teruhisa Takuwa, Seiji Matsumoto, Seiki Hasegawa, Hiroshi Doi
Publikováno v:
Cancer Research. 76:2488-2488
Background: The prognosis of Malignant pleural mesothelioma (MPM) is very poor, the new drug for MPM is need. IL-6 in serum with MPM patients is high, IL-6/Stat3 pathway is activated. We investigated that Stat3 is the potential target for the treatme